Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521269 | 0.84 | HTT (0.45) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL26999328 | 0.82 | MMP8 (0.34) | MMP8 | |
| SCHEMBL7857447 | 0.81 | MMP8 (0.59) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL28261535 | 0.81 | TSHR (0.42) | MMP8CYP4F2CYP4A11MAPK1 | |
| SCHEMBL22590295 | 0.81 | MMP8 (0.35) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL22562731 | 0.80 | MMP8 (0.42) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL24059176 | 0.79 | MMP8 (0.41) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL22481807 | 0.78 | MMP8 (0.38) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL20100216 | 0.77 | ALDH1A1 (0.34) | MMP8MAPK1HIF1A | |
| SCHEMBL16638216 | 0.76 | MMP8 (0.39) | MMP8CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873374-B2 | Swellable and structurally homogenous hydrogels and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-01-16 | — | — | US | disclosed |
| US-20200054592-A1 | NOVEL SMALL MOLECULE ANTICANCER AGENTS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054592-A1 | NOVEL SMALL MOLECULE ANTICANCER AGENTS | MKI67, TP53, PCNA | MMP8 1993/4885CYP4F2 4752/4885CYP4A11 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.